Ciltacabtagene autoleucel vs Zevorcabtagene autoleucel
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA · full Multiple Myeloma pipeline
Ciltacabtagene autoleucel
Marketed by Johnson & Johnson under a licence from Legend Biotech Corporation
NCT04181827 · Phase 3 · active, not recruiting
This was a large randomized phase 3 trial against active standard therapy, and its primary endpoint, progression-free survival, clearly favoured cilta-cel (hazard ratio 0.26, P<0.001). However, it was open-label: patients and doctors knew which treatment was given, so the evidence is rated below the top level.
Next expected readout: February 2027 · NCT04133636 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) (From randomization (Day 1) to either progressive disease or death, whichever occurred first (up to 3.9 years)): Progression-free survival: median not reached with cilta-cel vs 11.8 months with standard care (hazard ratio 0.26; 95% CI 0.18 to 0.38; P<0.001); 12-month PFS 75.9% vs 48.6% (CARTITUDE-4, N Engl J Med 2023). (met)
Result source: NCT04181827
Zevorcabtagene autoleucel
Marketed by Hangzhou Zhongmei Huadong Pharmaceutical and partners
NCT03975907 · Phase 1/2 · status unknown
This study enrolled every patient into a single treatment group, with no comparison arm and no blinding, so there is no control group to judge the response rate against. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The registered phase 1 primary endpoint of this study is dose-limiting toxicity; the response rates shown are the phase 2 portion's primary endpoint (overall response rate).
Reported efficacy
Phase 1, Safety and tolerability: dose limiting toxicity (28days post administration of CAR-T-cells); Phase 2, efficacy of CT053 CAR-BCMA T cells: overall response rate (3 months post administration of CAR-T-cells): LUMMICAR STUDY 1 phase II portion in 102 Chinese patients with relapsed/refractory multiple myeloma: overall response rate 92.2%, with 68.6% of patients achieving stringent complete response (sCR). (met)
Result source: NCT03975907
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Ciltacabtagene autoleucel | Zevorcabtagene autoleucel |
|---|---|---|
| PFS, median | —Trial running · NCT05257083 | —Not reported |
| OS, median | 27.0bNCT03548207 | —Not reported |
| ORR | 97.1%bNCT035482072 other results
| —Not reported |
| VGPR or better | 96.6%bNCT035482072 other results
| —Not reported |
| MRD negativity | 100%bNCT035482072 other results
| —Not reported |
PFS, median
- Ciltacabtagene autoleucel
- —Trial running · NCT05257083
- Zevorcabtagene autoleucel
- —Not reported
OS, median
- Ciltacabtagene autoleucel
- 27.0bNCT03548207
- Zevorcabtagene autoleucel
- —Not reported
ORR
- Ciltacabtagene autoleucel
- 97.1%bNCT03548207
2 other results
- 57.3% NCT05347485
- 100% NCT03548207
- Zevorcabtagene autoleucel
- —Not reported
VGPR or better
- Ciltacabtagene autoleucel
- 96.6%bNCT03548207
2 other results
- 94.1% NCT03548207
- 100% NCT03548207
- Zevorcabtagene autoleucel
- —Not reported
MRD negativity
- Ciltacabtagene autoleucel
- 100%bNCT03548207
2 other results
- 89.7% NCT03548207
- 75% NCT03548207
- Zevorcabtagene autoleucel
- —Not reported
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Ciltacabtagene autoleucel: 2 of 4 rows · Zevorcabtagene autoleucel: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ciltacabtagene autoleucel |
|---|---|
| Dropout rate | n/a: no completion milestonea NCT04181827 · Phase 3 · Multiple Myeloma · phase 3 show 4 more resultsn/a: no completion milestonePhase 1b (US Population) NCT03548207 · Phase 1/2 n/a: no completion milestonePhase 2 (Japan Population) NCT03548207 · Phase 1/2 n/a: no completion milestonePhase 2 (US Population) NCT03548207 · Phase 1/2 n/a: no completion milestone NCT05347485 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT04181827 · Phase 3 · Multiple Myeloma · phase 3 show 4 more results—Phase 1b (US Population) NCT03548207 · Phase 1/2 —Phase 2 (Japan Population) NCT03548207 · Phase 1/2 —Phase 2 (US Population) NCT03548207 · Phase 1/2 — NCT05347485 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 47.1%a NCT04181827 · Phase 3 · Multiple Myeloma · phase 3 show 4 more results37.9%Phase 1b (US Population) NCT03548207 · Phase 1/2 11.1%Phase 2 (Japan Population) NCT03548207 · Phase 1/2 61.8%Phase 2 (US Population) NCT03548207 · Phase 1/2 51.2% NCT05347485 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a neutropenia 89.9% cytokine release syndrome 62% thrombocytopenia 54.3% NCT04181827 · Phase 3 · Multiple Myeloma · phase 3 show 4 more resultsneutropenia 80.5% anaemia 59.8% cytokine release syndrome 57.3% NCT05347485 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 4 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ciltacabtagene autoleucel
show 2 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 27 more results
show 27 more results
show 27 more results
+ 5 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ciltacabtagene autoleucel's landscape · Zevorcabtagene autoleucel's landscape